A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
- Conditions
- Interventions
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1147
- Registration Number
- NCT01618669
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Mobile Heart Specialists, PC, Mobile, Alabama, United States
🇺🇸HOCC - New Britain Campus, New Britain, Connecticut, United States
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- First Posted Date
- 2012-05-28
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT01606982
Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01597986
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01585233
- Locations
- 🇦🇺
Specialist Connect, Brisbane, Queensland, Australia
🇨🇦Ultranova Skincare, Barrie, Ontario, Canada
🇦🇺CMAX, Adelaide, Victoria, Australia
Drug Interaction Study of Isavuconazole and Methadone
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01582425
- Locations
- 🇺🇸
Parexel International, LLC, Glendale, California, United States
Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01582399
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
Drug Interaction Study of Isavuconazole and Digoxin
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01582412
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT01565720
- Locations
- 🇺🇸
Parexel, Glendale, California, United States
Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT01565681
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 289
- Registration Number
- NCT01565655
- Locations
- 🇲🇽
Cliditer S.A. de C.V., México, Distrito Federal, Mexico
🇵🇱Zespol Poradni Specjalistycznych, REUMED sp. Zo.o, Lublin, Poland
🇧🇬MHAT Burgas, Burgas, Bulgaria